Bruker initiated with a Buy at Rothschild & Co Redburn

Rothschild & Co Redburn initiated coverage of Bruker (BRKR) with a Buy rating and $60 price target representing 41% potential upside. Bruker has underperformed its life science equipment peers year-to-date, with revenue and margins pressured by academic and government budget cuts and tariffs, the analyst tells investors in a research note. However, the firm views the company as well positioned to return to above-market earnings growth from 2026, given its leadership in proteomics and demand for next-generation systems such as mass spectrometry.